Dr. Gülnihal Özcan received her MD degree from Hacettepe University School of Medicine in 2007. She completed her residency in Pharmacology at Ankara University School of Medicine in 2011 and investigated signaling mechanisms of G-protein coupled receptors. In the context of public service responsibility, she was employed in the Ministry of Health Turkish Medicines and Medical Devices Agency and conducted studies on pharmacovigilance at Turkish Pharmacovigilance Center. In the same period she gained experience in bioinformatics and systems biology at Middle East Technical University in the context of special student program at Physics and Biomedical Engineering PhD program. She conducted her post-doctoral studies at University of Texas MD Anderson Cancer Center Department of Experimental Therapeutics. Since 2016, she has been conducting studies on the mechanisms of chemoresistance in gastric cancer and ovarian cancer at Koç University School of Medicine. Her major research interests are mechanisms of chemoresistance in cancer and systems pharmacology.
Ozcan G, Aykac E, Kasap Y, Nemutlu NT, Sen E, Aydinkarahaliloglu ND. Adverse Drug Reaction Reporting Pattern in Turkey: Analysis of the National Database in the Context of the First Pharmacovigilance Legislation. Drugs – Real World Outcomes 2016;3(1):33-43.
Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopez-Berestein G. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015 Jun 29;87:108-19.
Kaya AI, Onaran HO, Özcan G, Ambrosio C, Costa T, Balli S, Ugur Ö. Cell contact-dependent functional selectivity of β2-adrenergic receptor ligands in stimulating cAMP accumulation and extracellular signal-regulated kinase phosphorylation. J Biol Chem. 2012 Feb 24;287(9):6362- 74.